A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis

In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1–2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician’s choice (dex...

Descripción completa

Detalles Bibliográficos
Autores principales: Dispenzieri, Angela, Kastritis, Efstathios, Wechalekar, Ashutosh D., Schönland, Stefan O., Kim, Kihyun, Sanchorawala, Vaishali, Landau, Heather J., Kwok, Fiona, Suzuki, Kenshi, Comenzo, Raymond L., Berg, Deborah, Liu, Guohui, Kumar, Arun, Faller, Douglas V., Merlini, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727292/
https://www.ncbi.nlm.nih.gov/pubmed/34168284
http://dx.doi.org/10.1038/s41375-021-01317-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727292/
https://www.ncbi.nlm.nih.gov/pubmed/34168284
http://dx.doi.org/10.1038/s41375-021-01317-y

Ejemplares similares